Topic Completed: 1 January 2012

Minor changes: 2 June 2020

Copyright: 2003-2019,, Inc.

PubMed Search: BRAF[title]

See also BRAF-melanoma

Nat Pernick, M.D.
Page views in 2019: 3,649
Page views in 2020 to date: 2,680
Cite this page: Pernick N. BRAF. website. Accessed August 8th, 2020.
Definition / general
  • Serine / threonine specific protein kinase, part of the RAS / MAPK pathway regulating the growth, maturation, proliferation, survival and apoptosis of cells
  • Abbreviation for v-raf murine sarcoma viral oncogene homolog B1
  • Gene commonly mutated in papillary thyroid carcinoma and melanoma
  • V600E mutation (valine at residue 600 replaced by glutamic acid) renders BRAF constitutively active and increases its kinase activity (Nature 2002;417:949)
  • IHC with VE1 antibody is highly sensitive and specific to detect BRAF V600E mutation (Virchows Arch 2015;467:155)
Diagrams / tables
Images hosted on other servers:

MAPK signaling pathway

Clinical features
  • The drug Vemurafenib / Zelboraf®, used to treat melanoma, interrupts the BRAF / MEK / ERK pathway, only when BRAF has the V600E mutation (valine replaced by glutamic acid)
Uses by pathologists
Microscopic (histologic) images
Images hosted on PathOut server:

Courtesy of Andrey Bychkov, M.D., Ph.D.

V600E mutant protein is diffusely expresed in tumor / cancer, but not normal tissue

Diffuse cytoplasmic staining

Images hosted on other servers:

Prevalence of BRAF mutations
in different histologic variants
of thyroid papillary carcinoma

Negative stains
Molecular / cytogenetics description
Molecular / cytogenetics images
Images hosted on other servers:

BRAF melting curves

Back to top